Clearly, both GDNF and soluble sAPPα levels are altered in fluids from patients with intermediate and fast progression of the disease, indicating that GDNF and soluble APP are biomarkers of ALS pathophysiology. Here, GDNF is linked to amyotrophic lateral sclerosis.